Eine "Blut-Aktie"......... - 500 Beiträge pro Seite
eröffnet am 17.11.01 16:16:26 von
neuester Beitrag 21.11.01 09:05:49 von
neuester Beitrag 21.11.01 09:05:49 von
Beiträge: 5
ID: 507.094
ID: 507.094
Aufrufe heute: 0
Gesamt: 481
Gesamt: 481
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
11.05.24, 11:52 | 3866 | |
vor 1 Stunde | 2983 | |
gestern 20:09 | 2727 | |
gestern 18:51 | 2281 | |
gestern 20:02 | 1973 | |
08.05.24, 11:56 | 1972 | |
gestern 20:31 | 1657 | |
vor 1 Stunde | 1595 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 0,2170 | +3,33 | 48 | |||
2. | 2. | 18.763,00 | -0,01 | 44 | |||
3. | 3. | 168,47 | -2,04 | 26 | |||
4. | 4. | 0,1640 | 0,00 | 21 | |||
5. | 5. | 2,5600 | -6,91 | 17 | |||
6. | 6. | 0,2980 | -3,87 | 17 | |||
7. | 7. | 898,78 | +1,27 | 13 | |||
8. | 8. | 10,320 | 0,00 | 12 |
machte diese Woche auf sich aufmerksam:
HyperBaric Systems (HYRB.OB / # 806614)
Sind hier Mediziner/Medizinstudenten im Board, die ein kurzes Statement zu untenstehender Meldung abgeben könnten.
Interessant wäre es zu wissen, ob hier wirklich ein Markt vorhanden ist bzw.entstehen könnte.
Dann wäre wohl auch eine enorm positive Zukunft dieser Aktie zu erwarten.
Vielen Dank für ernstgemeinte Antworten.
HyperBaric Systems Validates Platelet Preservation Technology
PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 15, 2001--HyperBaric Systems (OTCBB:HYRB - news) has achieved successful confirmation of its proprietary blood platelet preservation technology and is continuing its groundbreaking experiments at The Center for Blood Research in Sacramento.
Dr. David Lucas, Scientific Director for HyperBaric, had previously announced that experiments at its laboratory in Russia had demonstrated successful platelet function after ten days of cold storage.
``So far we have replicated our experiments in Sacramento for eight days and confirmed results achieved in Russia,`` he said. ``During the period when experiments in Sacramento were being conducted, we attained additional significant improvements in Russia that we want to implement as soon as possible.``
Dr. Lucas noted that, ``The majority of decay in platelets under refrigerated conditions takes place within the first 24 hours then becomes minimal thereafter. We have just recently discovered a significant enhancement to our cold-temperature technology that dramatically reduces the initial impact of cooling on the platelets. This is another very important achievement in the ongoing refinement of our platelet preservation technology.``
``We want to continue our experiments at The Center for Blood Research, implementing our new findings, and attain preservation periods exceeding ten days,`` Dr. Lucas stated.
``Our attention is now focused on these exciting new improvements and making arrangements with regulatory authorities to move forward with human infusion clinical studies.``
Before HyperBaric`s breakthrough technology, experiments to store blood platelets in refrigerated conditions were attempted for more than forty years without success.
``In less than four years we have accomplished major achievements in the field of blood platelet preservation, what others have not done in the past forty years. This is just the beginning,`` Harry Masuda, HyperBaric President said.
``I believe our technology is going to save millions of dollars for blood banks, hospitals and medical centers. More importantly I believe we will save thousands of lives worldwide,`` he added.
Blood platelets, the congealing component of blood, are essential for use in patients undergoing chemotherapy treatments, organ transplants and major surgery.
``Currently, nearly half of the world`s population has no access to blood platelets, primarily due to logistics created by their very limited shelf life,`` Bob Strom Vice President of Sales and Marketing said.
``Our extended preservation technology will allow the shipping of platelets to any global point and make inventory control a much easier task for the agencies involved.``
The new proprietary technology from HyperBaric Systems also helps solve the problem of bacterial damage to blood platelets by virtually halting all pathogen growth.
Bacterial growth during room temperature storage is considered to be one of the major dilemmas of platelet use.
``We don`t create any additional costs in eliminating bacterial problems, because it is a natural result of our cold temperature technology,`` Dr. Lucas said.
HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area and Rancho Mirage, California. The company also has research and testing facilities in Russia and Michigan.
HyperBaric Systems (HYRB.OB / # 806614)
Sind hier Mediziner/Medizinstudenten im Board, die ein kurzes Statement zu untenstehender Meldung abgeben könnten.
Interessant wäre es zu wissen, ob hier wirklich ein Markt vorhanden ist bzw.entstehen könnte.
Dann wäre wohl auch eine enorm positive Zukunft dieser Aktie zu erwarten.
Vielen Dank für ernstgemeinte Antworten.
HyperBaric Systems Validates Platelet Preservation Technology
PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 15, 2001--HyperBaric Systems (OTCBB:HYRB - news) has achieved successful confirmation of its proprietary blood platelet preservation technology and is continuing its groundbreaking experiments at The Center for Blood Research in Sacramento.
Dr. David Lucas, Scientific Director for HyperBaric, had previously announced that experiments at its laboratory in Russia had demonstrated successful platelet function after ten days of cold storage.
``So far we have replicated our experiments in Sacramento for eight days and confirmed results achieved in Russia,`` he said. ``During the period when experiments in Sacramento were being conducted, we attained additional significant improvements in Russia that we want to implement as soon as possible.``
Dr. Lucas noted that, ``The majority of decay in platelets under refrigerated conditions takes place within the first 24 hours then becomes minimal thereafter. We have just recently discovered a significant enhancement to our cold-temperature technology that dramatically reduces the initial impact of cooling on the platelets. This is another very important achievement in the ongoing refinement of our platelet preservation technology.``
``We want to continue our experiments at The Center for Blood Research, implementing our new findings, and attain preservation periods exceeding ten days,`` Dr. Lucas stated.
``Our attention is now focused on these exciting new improvements and making arrangements with regulatory authorities to move forward with human infusion clinical studies.``
Before HyperBaric`s breakthrough technology, experiments to store blood platelets in refrigerated conditions were attempted for more than forty years without success.
``In less than four years we have accomplished major achievements in the field of blood platelet preservation, what others have not done in the past forty years. This is just the beginning,`` Harry Masuda, HyperBaric President said.
``I believe our technology is going to save millions of dollars for blood banks, hospitals and medical centers. More importantly I believe we will save thousands of lives worldwide,`` he added.
Blood platelets, the congealing component of blood, are essential for use in patients undergoing chemotherapy treatments, organ transplants and major surgery.
``Currently, nearly half of the world`s population has no access to blood platelets, primarily due to logistics created by their very limited shelf life,`` Bob Strom Vice President of Sales and Marketing said.
``Our extended preservation technology will allow the shipping of platelets to any global point and make inventory control a much easier task for the agencies involved.``
The new proprietary technology from HyperBaric Systems also helps solve the problem of bacterial damage to blood platelets by virtually halting all pathogen growth.
Bacterial growth during room temperature storage is considered to be one of the major dilemmas of platelet use.
``We don`t create any additional costs in eliminating bacterial problems, because it is a natural result of our cold temperature technology,`` Dr. Lucas said.
HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area and Rancho Mirage, California. The company also has research and testing facilities in Russia and Michigan.
also nicht Mal Sonntags sind hier "Mediziner" oder "Insider" ? !
Falls doch.......wäre eine kurze Stellungnahme zu obigem
-sehr spekulativen- Wert sehr nett.
Falls doch.......wäre eine kurze Stellungnahme zu obigem
-sehr spekulativen- Wert sehr nett.
Montags auch nicht ?
schliesse hiermit "meinen" Thread ab.
Melde mich wieder , wenn diese Aktie über 5,-- $ steht....nicht aber, wenn sie wertlos wurde.
Schöner Tag noch.
Melde mich wieder , wenn diese Aktie über 5,-- $ steht....nicht aber, wenn sie wertlos wurde.
Schöner Tag noch.
Hallo,
schau mal unter HEMOSOL nach. Da tummeln
sich einige Medizinspezialisten !!
schau mal unter HEMOSOL nach. Da tummeln
sich einige Medizinspezialisten !!
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
48 | ||
44 | ||
27 | ||
21 | ||
17 | ||
17 | ||
13 | ||
12 | ||
10 | ||
10 |
Wertpapier | Beiträge | |
---|---|---|
9 | ||
7 | ||
7 | ||
7 | ||
7 | ||
7 | ||
6 | ||
6 | ||
5 | ||
5 |